Interestingly, Teff/Treg ratio increased for CD4+ and CD8+ suggesting that cyclophosphamide may inhibit Tregs thereby stimulating the effector T cells, functional effect of these data was evidenced by reduced tumor weights when cyclophosphamide was administered before each immunotherapy cycle [65]. Here, CD8A is linked to neoplasm.